Log in

ASX:OSPOsprey Medical Stock Price, Forecast & News

0.0090
0.00 (0.00 %)
(As of 05/13/2020)
Add
Compare
Today's Range
A$0.01
Now: A$0.01
A$0.01
50-Day Range
A$0.01
MA: A$0.01
A$0.01
52-Week Range
A$0.01
Now: A$0.01
A$0.12
Volume1.25 million shs
Average VolumeN/A
Market Capitalization$7.77 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Osprey Medical, Inc., a commercial stage company, focuses on protecting patients from the harmful effects of X-ray dye used during commonly performed angiographic imaging procedures in the United States and internationally. It offers AVERT, AVERT Plus, DyeVert Plus System, and DyeVert System, which reduces and monitors the contrast dye used in commonly performed heart, cardiovascular, and peripheral procedures. The company was founded in 2005 and is headquartered in Minnetonka, Minnesota.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.71 out of 5 stars


Industry, Sector and Symbol

Industry Medical Devices
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone952-955-8230

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.67 million
Cash FlowA$0.02 per share
Book ValueA$0.02 per share

Profitability

Miscellaneous

EmployeesN/A
Market Cap$7.77 million
Next Earnings DateN/A
OptionableNot Optionable

Receive OSP News and Ratings via Email

Sign-up to receive the latest news and ratings for OSP and its competitors with MarketBeat's FREE daily newsletter.

Osprey Medical (ASX:OSP) Frequently Asked Questions

How were Osprey Medical's earnings last quarter?

Osprey Medical Inc (ASX:OSP) issued its quarterly earnings results on Wednesday, August, 14th. The company reported ($0.04) EPS for the quarter. View Osprey Medical's earnings history.

Has Osprey Medical been receiving favorable news coverage?

Media coverage about OSP stock has trended very negative on Thursday, according to InfoTrie. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Osprey Medical earned a news sentiment score of -3.0 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news aboutOsprey Medical.

Who are some of Osprey Medical's key competitors?

What other stocks do shareholders of Osprey Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Osprey Medical investors own include Macquarie Group (MQG), Magellan Financial Group (MFG), Medlab Clinical (MDC), FBR (FBR), Evolve Education Group (EVO), Dacian Gold (DCN), CCP Technologies (CT1), Bingo Industries (BIN), Afterpay Touch Group (APT) and Alkane Resources (ALK).

Who are Osprey Medical's key executives?

Osprey Medical's management team includes the following people:
  • Mr. Michael McCormick, Pres, CEO & Exec. Director (Age 57)
  • Dr. J. Edward Shapland, Co-Founder
  • Ms. Nancy Ness, VP of Fin. & CFO
  • Mr. Vic Fabano, VP of Operations & IT (Age 57)
  • Ms. Melanie Hess, VP of Regulatory Affairs, Compliance & Quality

What is Osprey Medical's stock symbol?

Osprey Medical trades on the ASX under the ticker symbol "OSP."

What is Osprey Medical's stock price today?

One share of OSP stock can currently be purchased for approximately A$0.01.

How big of a company is Osprey Medical?

Osprey Medical has a market capitalization of $7.77 million and generates $3.67 million in revenue each year.

What is Osprey Medical's official website?

The official website for Osprey Medical is www.ospreymed.com.

How can I contact Osprey Medical?

The company can be reached via phone at 952-955-8230.

This page was last updated on 6/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.